A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.

Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients – and it's exactly what President Donald Trump wants.

Amgen is the latest company to wade into the direct-to-consumer space, announcing on Monday that it will offer its cholesterol-lowering drug Repatha at a cash price 60% below its current list price before insurance and rebates. It follows similar moves by other drugmakers to simplify how Americans get their medicines and political pressure from the Trump administration to lower U.S. drug prices.

Trump in July sent letters to 17 drugmak

See Full Page